Motor subtype change between OFF and ON periods in patients with Parkinson’s disease
Objective: To identify if there is any difference in the motor subtype of PwPD between "off" stage and "on" stage. Background: Patients with Parkinson’s disease…12-month therapeutic evaluation of l-dopa carbidopa ascorbic acid solution (LCAS) in a cohort of Advanced Parkinson’s disease in a North-Indian tertiary care hospital
Objective: To prescribe LCAS to Parkinson’s disease(PD) patients whose symptoms were not adequately controlled on tablet l-dopa and compare the UPDRS-(I,II,III,IV) ON & OFF on…Sensorimotor inhibition relates to gait dysfunction in people with Parkinson’s disease
Objective: To determine how sensorimotor inhibition relates to objective measures of gait OFF and ON levodopa and how having Parkinson’s disease (PD) affects this relationship.…Claims Data Analysis of Parkinson’s Disease Medication Utilization
Objective: Characterize prominent medication utilization patterns among patients with Parkinson’s disease (PD). Background: Multiple classes of medications, as monotherapy or polytherapy, are prescribed to treat…Pill burden reduction in patients with advanced Parkinson’s disease: Comparative effectiveness of carbidopa/levodopa enteral suspension and Deep brain stimulation
Objective: To compare the real-world impact of initiating carbidopa/levodopa enteral suspension (CLES) or deep brain stimulation (DBS) on reducing pill burden (i.e. total number of…Parkinson’s disease and osteocalcin pilot study: Is there a protective role of bone in neurodegeneration?
Objective: To characterize the relationship between the bone-derived hormone osteocalcin (OCN) and Parkinson’s disease (PD) in humans, and explore sex and treatment differences. Background: The…Impact of dopamine 2/3 receptor agonists on the phenomenology of L-DOPA-induced dyskinesia in patients with Parkinson’s disease
Objective: To investigate possible differences in phenomenology and temporal profile of dyskinesias in patients with Parkinson’s disease (PD) after challenge doses with levodopa alone or…Efficacy and safety of levodopa-carbidopa intestinal gel (LCIG) for advanced Parkinson’s disease: a Turkish single-centre experience
Objective: This study is aimed to investigate the efficacy and adverse effect profile of LCIG among advanced PD patients from a Turkish movement disorder center.…Population pharmacokinetic analysis of levodopa and carbidopa after subcutaneous administration with and without adjunct oral therapy
Objective: To develop population pharmacokinetic (PK) models for levodopa (LD) and carbidopa (CD) following subcutaneous (SC) infusion, including adjunct oral LD/CD administration. Background: ND0612 is…Monitoring electrophysiological recordings in patients with LCIJ therapy
Objective: Levodopa carbidopa intestinal jel (LCIJ) treatment for advanced Parkinson’s disease patients is live-saving for the appropriate patients, however follow up of the patients has…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 62
- Next Page »